Showing results (281-290 of 367) with videos related to

Sort By:
Pageof 37
Frontiers in Oncology|July 8, 2025
Part I: consensus statements and expert recommendations for HER2-negative early breast cancer in the Asia-Pacific region: diagnosis and risk assessmentSoo Chin Lee, Yeon Hee Park, Christian F Singer, et al.
Scientific Reports|March 16, 2019
Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicatorBo Young Oh, Hyun-Tae Shin, Jae Won Yun, et al.
NPJ Breast Cancer|September 12, 2024
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBCSeock-Ah Im, Javier Cortes, David W Cescon, et al.
Frontiers in Oncology|July 8, 2025
Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical managementYeon Hee Park, Soo Chin Lee, Christian F Singer, et al.
Cancers|October 14, 2022
Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective CohortHyunji Jo, Seri Park, Hye Ryeon Kim, et al.
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
The New England Journal of Medicine|October 29, 2025
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast CancerSara M Tolaney, Zefei Jiang, Qingyuan Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2023
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)Se Hyun Kim, Seock-Ah Im, Koung Jin Suh, et al.
Cancer Research and Treatment|February 21, 2018
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)In Hae Park, Seock-Ah Im, Kyung Hae Jung, et al.
Biochemical and Biophysical Research Communications|April 24, 2016
Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistanceJeong Eun Lee, Hee Sun Park, Dahye Lee, et al.
Pageof 37